Dr Loretta Lau

Senior Lecturer
Paediatrics & Child Health, Children's Hospital, Westmead

Telephone +61 2 9845-3115
Fax +61 2 9845-1317

Website Related website

Map

Biographical details

Dr Loretta Lau is the leader of the Neuroblastoma Research Group at the Children's Cancer Research Unit, Kids Research Institute, The Children's Hospital at Westmead. She is also a Senior Lecturer of the Discipline of Paediatrics and Child Health, Sydney Medical School, University of Sydney. She was the Clinical Research Fellow of the Cancer Institute of NSW (2008 - 2010) and is currently a NHMRC Early Career Research Fellow (2011 - 2014). She has received project grants from Cure Cancer Australia Foundation, Pablove Foundation (USA), Clive and Ramaciotti Foundation, and NHMRC.

Dr Lau obtained her medical degree from the University of Sydney, followed by a Master of Medicine in Clinical Epidemiology. She did her training in paediatric oncology at The Children's Hospital at Westmead and is a Fellow of the Royal Australasian College of Physicians. Loretta then spent 6 years in Canada to pursue further clinical and research training in paediatric oncology at The Hospital for Sick Children in Toronto, during which she completed a PhD focusing on neuroblastoma research. Her goal as a clinician-scientist is to bridge the "gap" between scientific progress in the laboratory and better treatment at the bedside.

Research interests

Dr Loretta Lau is a clinician-scientist and paediatric oncologist. Her major research interest is neuroblastoma, a common childhhod cancer. Her laboratory research group located at The Children's Hospital at Westmead focuses on telomere biology and telomnere length maintenance in neuroblastoma and alternative lengthening of telomeres.

Selected grants

2013

  • A novel mechanism for sustained proliferation of cancer cells; Reddel R, Lau L; National Health and Medical Research Council (NHMRC)/Project Grants.

2012

  • Interaction of TRF2 with DNA repair proteins in Alternative Lengthening of Telomeres; Braithwaite A, Reddel R, Lau L; National Health and Medical Research Council (NHMRC)/Project Grants.

2011

  • Telomere Maintenance in Neuroblastoma; Lau L; National Health and Medical Research Council (NHMRC)/Early Career Fellowships (ECF).
  • Telomere Maintenance in Neuroblastoma; Lau L; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2008

  • Selective Targeting of the Actin Cytoskeleton in Cancer Therapy; Lau L; Cancer Institute New South Wales/Clinical Research Fellowship (CRF).

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Farooqi, A., Dagg, R., Choi, L., Shay, J., Reynolds, C., Lau, L. (2014). Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. Journal of Neuro-Oncology, 119(1), 17-26. [More Information]
  • Lee, M., Hills, M., Conomos, D., Stutz, M., Dagg, R., Lau, L., Reddel, R., Pickett, H. (2014). Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes. Nucleic Acids Research, 42(3), 1733-1746. [More Information]
  • Lau, L., Dagg, R., Henson, J., Au, A., Royds, J., Reddel, R. (2013). Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Research, 41(2), 1-9. [More Information]
  • Bower, K., Napier, C., Cole, S., Dagg, R., Lau, L., Duncan, E., Moy, E., Reddel, R. (2012). Loss of Wild-Type ATRX Expression in Somatic Cell Hybrids Segregates with Activation of Alternative Lengthening of Telomeres. PLoS One, 7(11), 1-10. [More Information]
  • Lau, L., Nugent, J., Zhao, X., Irwin, M. (2008). HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene, 27(7), 997-1003. [More Information]
  • Lau, L., Stuurman, K., Weitzman, S. (2008). Skeletal langerhans cell histiocytosis in children: Permanent consequences and health-related quality of life in long-term survivors. Pediatric Blood and Cancer, 50(3), 607-612. [More Information]
  • Lau, L., Hansford, L., Cheng, L., Hang, M., Baruchel, S., Kaplan, D., Irwin, M. (2007). Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene, 26(13), 1920-1931. [More Information]
  • Lau, L., Hargrave, D., Bartels, U., Esquembre, C., Bouffet, E. (2006). Childhood brain tumour information on the Internet in the Chinese language. Child's Nervous System, 22(4), 346-351. [More Information]
  • Lau, L., Krafchik, B., Trebo, M., Weitzman, S. (2006). Cutaneous Langerhans Cell Histiocytosis in Children Under One Year. Pediatric Blood and Cancer, 46(1), 66-71. [More Information]
  • Odame, I., Li, P., Lau, L., Doda, W., Noseworthy, M., Babyn, P., Weitzman, S. (2006). Pulmonary Langerhans cell histiocytosis: A variable disease in childhood. Pediatric Blood and Cancer, 47(7), 889-893. [More Information]
  • Lau, L., Supko, J., Blaney, S., Hershon, L., Seibel, N., Krailo, M., Qu, W., Malkin, D., Jimeno, J., Bernstein, M., et al (2005). A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clinical Cancer Research, 11(2I), 672-677. [More Information]
  • Lau, L., Baruchel, S. (2005). Can Canada sustain paediatric phase I trials? A national survey of cancer relapse in children. Canadian Journal of Clinical Pharmacology, 12(3), e222-e228. [More Information]
  • Shaw, P., Bleakley, M., Lau, L. (2004). Unrelated cord blood transplant as salvage following non-engraftment of unrelated marrow transplant? Bone Marrow Transplantation, 34(3), 275-276.
  • Hargrave, D., Bartels, U., Lau, L., Esquembre, C., Buffet, E. (2003). Quality of childhood brain tumor information on the Internet in French language. Bulletin du Cancer (Print), 90(7), 650-655.

2014

  • Farooqi, A., Dagg, R., Choi, L., Shay, J., Reynolds, C., Lau, L. (2014). Alternative lengthening of telomeres in neuroblastoma cell lines is associated with a lack of MYCN genomic amplification and with p53 pathway aberrations. Journal of Neuro-Oncology, 119(1), 17-26. [More Information]
  • Lee, M., Hills, M., Conomos, D., Stutz, M., Dagg, R., Lau, L., Reddel, R., Pickett, H. (2014). Telomere extension by telomerase and ALT generates variant repeats by mechanistically distinct processes. Nucleic Acids Research, 42(3), 1733-1746. [More Information]

2013

  • Lau, L., Dagg, R., Henson, J., Au, A., Royds, J., Reddel, R. (2013). Detection of alternative lengthening of telomeres by telomere quantitative PCR. Nucleic Acids Research, 41(2), 1-9. [More Information]

2012

  • Bower, K., Napier, C., Cole, S., Dagg, R., Lau, L., Duncan, E., Moy, E., Reddel, R. (2012). Loss of Wild-Type ATRX Expression in Somatic Cell Hybrids Segregates with Activation of Alternative Lengthening of Telomeres. PLoS One, 7(11), 1-10. [More Information]

2008

  • Lau, L., Nugent, J., Zhao, X., Irwin, M. (2008). HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function. Oncogene, 27(7), 997-1003. [More Information]
  • Lau, L., Stuurman, K., Weitzman, S. (2008). Skeletal langerhans cell histiocytosis in children: Permanent consequences and health-related quality of life in long-term survivors. Pediatric Blood and Cancer, 50(3), 607-612. [More Information]

2007

  • Lau, L., Hansford, L., Cheng, L., Hang, M., Baruchel, S., Kaplan, D., Irwin, M. (2007). Cyclooxygenase inhibitors modulate the p53/HDM2 pathway and enhance chemotherapy-induced apoptosis in neuroblastoma. Oncogene, 26(13), 1920-1931. [More Information]

2006

  • Lau, L., Hargrave, D., Bartels, U., Esquembre, C., Bouffet, E. (2006). Childhood brain tumour information on the Internet in the Chinese language. Child's Nervous System, 22(4), 346-351. [More Information]
  • Lau, L., Krafchik, B., Trebo, M., Weitzman, S. (2006). Cutaneous Langerhans Cell Histiocytosis in Children Under One Year. Pediatric Blood and Cancer, 46(1), 66-71. [More Information]
  • Odame, I., Li, P., Lau, L., Doda, W., Noseworthy, M., Babyn, P., Weitzman, S. (2006). Pulmonary Langerhans cell histiocytosis: A variable disease in childhood. Pediatric Blood and Cancer, 47(7), 889-893. [More Information]

2005

  • Lau, L., Supko, J., Blaney, S., Hershon, L., Seibel, N., Krailo, M., Qu, W., Malkin, D., Jimeno, J., Bernstein, M., et al (2005). A phase I and pharmacokinetic study of ecteinascidin-743 (Yondelis) in children with refractory solid tumors. A Children's Oncology Group study. Clinical Cancer Research, 11(2I), 672-677. [More Information]
  • Lau, L., Baruchel, S. (2005). Can Canada sustain paediatric phase I trials? A national survey of cancer relapse in children. Canadian Journal of Clinical Pharmacology, 12(3), e222-e228. [More Information]

2004

  • Shaw, P., Bleakley, M., Lau, L. (2004). Unrelated cord blood transplant as salvage following non-engraftment of unrelated marrow transplant? Bone Marrow Transplantation, 34(3), 275-276.

2003

  • Hargrave, D., Bartels, U., Lau, L., Esquembre, C., Buffet, E. (2003). Quality of childhood brain tumor information on the Internet in French language. Bulletin du Cancer (Print), 90(7), 650-655.

To update your profile click here. For support on your academic profile contact .